127 related articles for article (PubMed ID: 27861596)
21. Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.
Daud AI; Wolchok JD; Robert C; Hwu WJ; Weber JS; Ribas A; Hodi FS; Joshua AM; Kefford R; Hersey P; Joseph R; Gangadhar TC; Dronca R; Patnaik A; Zarour H; Roach C; Toland G; Lunceford JK; Li XN; Emancipator K; Dolled-Filhart M; Kang SP; Ebbinghaus S; Hamid O
J Clin Oncol; 2016 Dec; 34(34):4102-4109. PubMed ID: 27863197
[TBL] [Abstract][Full Text] [Related]
22. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study.
Hu LY; Xu XL; Rao HL; Chen J; Lai RC; Huang HQ; Jiang WQ; Lin TY; Xia ZJ; Cai QQ
Chin J Cancer; 2017 Dec; 36(1):94. PubMed ID: 29246182
[TBL] [Abstract][Full Text] [Related]
23. PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas.
Wang Y; Wu L; Tian C; Zhang Y
Ann Hematol; 2018 Feb; 97(2):229-237. PubMed ID: 29128997
[TBL] [Abstract][Full Text] [Related]
24. Biomarkers of response to PD-1/PD-L1 inhibition.
Maleki Vareki S; Garrigós C; Duran I
Crit Rev Oncol Hematol; 2017 Aug; 116():116-124. PubMed ID: 28693793
[TBL] [Abstract][Full Text] [Related]
25. PD-1/PD-L1 inhibitors in haematological malignancies: update 2017.
Jelinek T; Mihalyova J; Kascak M; Duras J; Hajek R
Immunology; 2017 Nov; 152(3):357-371. PubMed ID: 28685821
[TBL] [Abstract][Full Text] [Related]
26. Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
Farina MS; Lundgren KT; Bellmunt J
Drugs; 2017 Jul; 77(10):1077-1089. PubMed ID: 28493171
[TBL] [Abstract][Full Text] [Related]
27. Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.
Myklebust JH; Brody J; Kohrt HE; Kolstad A; Czerwinski DK; Wälchli S; Green MR; Trøen G; Liestøl K; Beiske K; Houot R; Delabie J; Alizadeh AA; Irish JM; Levy R
Blood; 2017 Feb; 129(6):759-770. PubMed ID: 28011673
[TBL] [Abstract][Full Text] [Related]
28. Targeting the PD-1/PD-L1 axis in multiple myeloma: a dream or a reality?
Rosenblatt J; Avigan D
Blood; 2017 Jan; 129(3):275-279. PubMed ID: 27919908
[TBL] [Abstract][Full Text] [Related]
29. New targeted therapies for malignant lymphoma based on molecular heterogeneity.
Horn H; Staiger AM; Ott G
Expert Rev Hematol; 2017 Jan; 10(1):39-51. PubMed ID: 27918211
[TBL] [Abstract][Full Text] [Related]
30. Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.
Shin DS; Zaretsky JM; Escuin-Ordinas H; Garcia-Diaz A; Hu-Lieskovan S; Kalbasi A; Grasso CS; Hugo W; Sandoval S; Torrejon DY; Palaskas N; Rodriguez GA; Parisi G; Azhdam A; Chmielowski B; Cherry G; Seja E; Berent-Maoz B; Shintaku IP; Le DT; Pardoll DM; Diaz LA; Tumeh PC; Graeber TG; Lo RS; Comin-Anduix B; Ribas A
Cancer Discov; 2017 Feb; 7(2):188-201. PubMed ID: 27903500
[TBL] [Abstract][Full Text] [Related]
31. Mantle Cell Lymphoma: Is It Time for a New Treatment Paradigm?
Goy A
Hematol Oncol Clin North Am; 2016 Dec; 30(6):1345-1370. PubMed ID: 27888885
[TBL] [Abstract][Full Text] [Related]
32. Lymphoblastic lymphoma with a triple-hit profile: a rare but distinct and relevant entity.
Hiemcke-Jiwa LS; Leguit RJ; van der Veken LT; Buijs A; Leeuwis JW; de Boer M; Jiwa NM; Bloem AC; Petersen EJ; de Weger RA; Huibers MMH
Hum Pathol; 2017 May; 63():171-176. PubMed ID: 27867103
[TBL] [Abstract][Full Text] [Related]
33. The role of anti-PD-1 and anti-PD-L1 agents in the treatment of diffuse large B-cell lymphoma: The future is now.
Juárez-Salcedo LM; Sandoval-Sus J; Sokol L; Chavez JC; Dalia S
Crit Rev Oncol Hematol; 2017 May; 113():52-62. PubMed ID: 28427522
[TBL] [Abstract][Full Text] [Related]
34. Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.
Davids MS; Roberts AW; Seymour JF; Pagel JM; Kahl BS; Wierda WG; Puvvada S; Kipps TJ; Anderson MA; Salem AH; Dunbar M; Zhu M; Peale F; Ross JA; Gressick L; Desai M; Kim SY; Verdugo M; Humerickhouse RA; Gordon GB; Gerecitano JF
J Clin Oncol; 2017 Mar; 35(8):826-833. PubMed ID: 28095146
[TBL] [Abstract][Full Text] [Related]
35. The influence of programmed cell death ligand 2 (PD-L2) expression on survival outcome and tumor microenvironment in diffuse large B cell lymphoma.
Krittikarux S; Wudhikarn K; Tangnuntachai N; Assanasen T; Sukswai N; Asawapanumas T; Chanswangphuwana C
Leuk Lymphoma; 2020 Dec; 61(14):3395-3403. PubMed ID: 32820659
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Significance of Immune-checkpoint Molecule PD-L1 in Classical Hodgkin Lymphoma: A Clinicopathologic Study of 120 Cases.
Kubes V; Kren L; Sokol F; Michalka J; Muzik J; Arpas T; Krenova Z; Kral Z
In Vivo; 2023; 37(4):1735-1742. PubMed ID: 37369476
[TBL] [Abstract][Full Text] [Related]
37. The effect of Wnt/β-catenin signaling on PD-1/PDL-1 axis in HPV-related cervical cancer.
Aghbash PS; Hemmat N; Baradaran B; Mokhtarzadeh A; Poortahmasebi V; Oskuee MA; Baghi HB
Oncol Res; 2022; 30(3):99-116. PubMed ID: 37305016
[TBL] [Abstract][Full Text] [Related]
38. Multi-targeted immunotherapeutics to treat B cell malignancies.
Gambles MT; Yang J; Kopeček J
J Control Release; 2023 Jun; 358():232-258. PubMed ID: 37121515
[TBL] [Abstract][Full Text] [Related]
39. PD-L1 and EBV LMP1 expressions in classic Hodgkin lymphomas and its correlation with clinicopathological parameters and prognosis.
Özdemir S; Ton Ö; Kabukcuoğlu F
Turk J Med Sci; 2022 Aug; 52(4):1013-1021. PubMed ID: 36326378
[TBL] [Abstract][Full Text] [Related]
40. PD-L1 testing by immunohistochemistry in immuno-oncology.
Vranic S; Gatalica Z
Biomol Biomed; 2023 Feb; 23(1):15-25. PubMed ID: 35964287
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
